Ever wondered how the latest advancements in GLP-1 medications are revolutionizing the treatment of diabetes and obesity? Join us for an insightful conversation with healthcare brokers Scott Scheiblin and Chip Wenges as they unravel the complexities and opportunities these groundbreaking drugs bring to healthcare providers. You'll discover the hidden pitfalls of improper prescribing practices, the looming threat of regulatory scrutiny over compounded medications, and the challenges posed by insurers limiting coverage to branded versions. As the demand for GLP-1s skyrockets, we discuss the implications and potential repercussions that could follow. Visit REDYIndex.com for critical pricing analysis and a snapshot of the marketplace. Do you want to take your career to the next level? Join #TeamCRC to get access to best-in-class tools, data, exclusive programs, and more! Send your resume to [email protected] today!

Ver todos los episodios